Elevation Oncology is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the ...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day. Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a ...

Lonza acquired Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of more effective and better tolerated antibody-drug conjugates ...

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of ...

We already see multiple signs of widespread willingness to exchange ideas and technology, with Seagen, Immunogen, Synaffix, and Byondis leading the pack in a number of joint ventures. Recently ...

The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the ...

17 March 2025 Hours after the swearing-in of the Secretary of Health and Human Services, Robert F Kennedy Jr (RFK), President Donald Trump issued an executive order establishing the Make America ...